Iovance Biotherapeutics, Inc. (IOVA) vs RadNet, Inc. (RDNT)
A side-by-side comparison of Iovance Biotherapeutics, Inc. and RadNet, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IOVA
Iovance Biotherapeutics, Inc.
$13.22HealthcareDelayed quote: Oct 6, 2026, 1:30 PM EDT
RDNT
RadNet, Inc.
$70.29HealthcareDelayed quote: Oct 6, 2026, 1:25 PM EDT
Total return — IOVA vs RDNT
growth of $100 · dividends reinvested · last 10yIOVA +87.7% (+6.5%/yr)RDNT +882.9% (+25.7%/yr)RDNT compounded faster over this window
Log scale — wide-divergence pair
IOVA RDNT
IOVA vs RDNT: by the numbers
- •IOVA is the larger company ($5.90B vs $5.53B market cap).
- •Both run net losses; RDNT's is the smaller (-0.93% vs -89.09% net margin).
Metrics side by side
Valuation
| Metric | IOVA | RDNT |
|---|---|---|
| Forward P/E | N/A | 136.67 |
| P/S ratio | 18.17 | 2.44 |
| P/B ratio | 8.02 | 5.04 |
| EV / EBITDA | N/A | 21.70 |
Profitability
| Metric | IOVA | RDNT |
|---|---|---|
| Gross margin | 97.23% | 9.70% |
| Operating margin | -153.08% | 4.00% |
| Net margin | -89.09% | -0.93% |
| ROE | -39.33% | -1.93% |
| ROIC | -37.26% | 1.41% |
Growth (annualized)
| Metric | IOVA | RDNT |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 12.68% |
| Total return CAGR (5Y) | -11.55% | 19.72% |
Frequently asked
- How have IOVA and RDNT total returns compared?
- Over the past 10 years, IOVA delivered 5.84% and RDNT delivered 25.20% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Iovance Biotherapeutics ROERadNet ROEIovance Biotherapeutics operating marginRadNet operating marginIovance Biotherapeutics revenue growthRadNet revenue growthIovance Biotherapeutics free cash flowRadNet free cash flow
Iovance Biotherapeutics & RadNet appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.